First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641

Completed · Phase 1

Conditions studied: Autoimmune Diseases, Multiple Sclerosis

In brief

A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Dose of LPX-TI641.

Key facts

Study ID

NCT05853835

Run by

LAPIX Therapeutics Inc.

People needed

72

Starts

2023-10-30

Expected to finish

2024-11-01

Last updated by the study team

2025-01-23

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

• AXIS Clinicals — Dilworth, Minnesota, United States
• Triumpharma clinical research unit at Alessra Hospital — Amman, Jordan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.